Enabling people to become the pilots of their own high-functional longevity.
With the first minimum viable platform for the health care industry to place cardiovascular geroprotection* into the hands of everyone.
Target Cardiovascular Aging!
"Because man is only as old as his arteries."
Thomas Sydenham, English physician, 1624-1689
Treating cardiovascular aging simultaneously prevents multiple aging-related diseases.
Uncover Biomarkers of Aging.
Aging and disease are defined as the gradual loss of function.
We therefore developed the first in-silico model of the CV system to
uncover its modifiable biomarkers of function and aging -
the CV functionome.
Create A Mimimum Viable Platform.
To help the health care industry test the benefits of geroprotection now.
Reducing the CVD burden (for health care payers)
Accelerating research (for pharma & biotech)
Defusing the demographic aging transition
Our Project Team
Klaus Reichenbach, Dipl. Ing.
Medical Technology Engineering,
Managing Director livetec Ingenieurbüro GmbH, Lörrach, Germany.
Our Funding Partners
The Development Pipeline
The following contains links to research from our team (in bold) and others, using websites owned and operated by third parties.
A novel principled method for the measurement of vascular robustness uncovers hidden risk for premature CVD death.
L. Kraushaar, A. Dressel …
Journal of Applied Physiology, 2018
The cardiovascular robustness hypothesis: Unmasking young adults’ hidden risk for premature cardiovascular death
L. Kraushaar, A. Dressel
Medical Hypotheses 2018
Strategies for Optimal Cardiovascular Aging
DR Seals et al.
Heart & Circulatory Physiology 2018
Substantial health and economic returns from delayed aging may warrant a new focus for medical research
Goldman, D. et al.
Health Affairs 2013